{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:12:33Z","timestamp":1790323953151,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"47-48","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.vaccine.2006.06.004","type":"journal-article","created":{"date-parts":[[2006,6,22]],"date-time":"2006-06-22T11:34:42Z","timestamp":1150976082000},"page":"6886-6892","source":"Crossref","is-referenced-by-count":35,"title":["Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice"],"prefix":"10.1016","volume":"24","author":[{"given":"John S.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Groebner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela G.","family":"Hadjipanayis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane L.","family":"Negley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Schmaljohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L.","family":"Welkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan F.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"48","key":"10.1016\/j.vaccine.2006.06.004_bib1","first-page":"1077","article-title":"Investigation of bioterrorism-related anthrax: Connecticut","volume":"50","year":"2001","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2006.06.004_bib2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1006\/viro.1997.8878","article-title":"Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterlogous pathogens in vivo","volume":"239","author":"Pushko","year":"1997","journal-title":"Virology"},{"issue":"17","key":"10.1016\/j.vaccine.2006.06.004_bib3","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1001\/jama.287.17.2236","article-title":"Anthrax as a biological weapon, 2002: updated recommendations for management","volume":"287","author":"Inglesby","year":"2002","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2006.06.004_bib4","series-title":"USAMRIID's medical management of biological casualties handbook","year":"2001"},{"issue":"3","key":"10.1016\/j.vaccine.2006.06.004_bib5","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1128\/IAI.70.3.1653-1656.2002","article-title":"A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection","volume":"70","author":"Flick-Smith","year":"2002","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.06.004_bib6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1046\/j.1365-2672.1999.00898.x","article-title":"Immune correlates of protection against anthrax","volume":"87","author":"Fowler","year":"1999","journal-title":"J Appl Microbiol"},{"issue":"18","key":"10.1016\/j.vaccine.2006.06.004_bib7","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0264-410X(95)00139-R","article-title":"Experimental anthrax vaccine: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs","volume":"13","author":"Ivins","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.06.004_bib8","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalation anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"issue":"6\/7","key":"10.1016\/j.vaccine.2006.06.004_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0264-410X(96)00286-1","article-title":"Anthrax post-vaccinal cell-mediated immunity in humans: kinetic patterns","volume":"15","author":"Shlyakhov","year":"1997","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.06.004_bib10","first-page":"33","article-title":"Anthrax vaccines","volume":"271","author":"Friedlander","year":"2002","journal-title":"Curr Top Microbiol Immunol"},{"issue":"21\/22","key":"10.1016\/j.vaccine.2006.06.004_bib11","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.vaccine.2003.12.027","article-title":"Development of an in vitro-based potency assay for anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2006.06.004_bib12","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1099\/0022-1317-51-10-821","article-title":"In-vitro characterization of the phagocytosis and fate of anthrax spores in macrophages and the effect of anti-PA antibody","volume":"51","author":"Welkos","year":"2002","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2006.06.004_bib13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.micpath.2005.02.001","article-title":"The detection of protective antigen (PA) associated with spores of Bacillus anthracis and the effects of anti-PA antibodies on spore germination and macrophage interactions","volume":"38","author":"Cote","year":"2005","journal-title":"Microb Pathog"},{"issue":"3","key":"10.1016\/j.vaccine.2006.06.004_bib14","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/IAI.71.3.1491-1496.2003","article-title":"Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge","volume":"71","author":"Lee","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.06.004_bib15","series-title":"Laboratory diagnosis of infectious diseases: principles and practice","first-page":"111","article-title":"Botulism","author":"Hatheway","year":"1988"},{"issue":"3","key":"10.1016\/j.vaccine.2006.06.004_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1128\/MMBR.44.3.419-448.1980","article-title":"Clostridial botulinum neurotoxin","volume":"44","author":"Sugiyama","year":"1980","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.vaccine.2006.06.004_bib17","series-title":"Botulinum neurotoxin and tetanus toxin","first-page":"351","article-title":"Botulism","author":"Tacket","year":"1989"},{"issue":"11","key":"10.1016\/j.vaccine.2006.06.004_bib18","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0041-0101(98)00146-9","article-title":"Development of recombinant vaccines for botulinum neurotoxin","volume":"36","author":"Smith","year":"1998","journal-title":"Toxicon"},{"issue":"7","key":"10.1016\/j.vaccine.2006.06.004_bib19","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1128\/IAI.63.7.2738-2742.1995","article-title":"Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed froma synthetic gene in Escherichia coli","volume":"63","author":"Clayton","year":"1995","journal-title":"Infect Immun"},{"issue":"10","key":"10.1016\/j.vaccine.2006.06.004_bib20","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1128\/IAI.66.10.4817-4822.1998","article-title":"Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate","volume":"66","author":"Byrne","year":"1998","journal-title":"Infect Immun"},{"issue":"3","key":"10.1016\/j.vaccine.2006.06.004_bib21","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1006\/prep.2000.1200","article-title":"Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris","volume":"18","author":"Byrne","year":"2000","journal-title":"Protein Exp Purif"},{"key":"10.1016\/j.vaccine.2006.06.004_bib22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0264-410X(99)00264-9","article-title":"The immunogenicity in humans of a botulinum type F vaccine","volume":"18","author":"Montgomery","year":"2000","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2006.06.004_bib23","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1128\/IAI.69.9.5709-5715.2001","article-title":"Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system","volume":"69","author":"Lee","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.06.004_bib24","series-title":"Fields virology","first-page":"1161","article-title":"Filoviridae: Marburg and Ebola viruses","author":"Peters","year":"1996"},{"key":"10.1016\/j.vaccine.2006.06.004_bib25","series-title":"Fields virology","first-page":"1279","article-title":"Filoviridae: Marburg and Ebola viruses","author":"Sanchez","year":"2001"},{"key":"10.1016\/j.vaccine.2006.06.004_bib26","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1016\/S0264-410X(03)00362-1","article-title":"Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus, and Venezuelan equine encephalitis virus","volume":"21","author":"Riemenschneider","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.06.004_bib27","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/S0264-410X(01)00353-X","article-title":"Marburg virus vaccines: comparing classical and new approaches","volume":"20","author":"Hevey","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2006.06.004_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1006\/viro.1998.9367","article-title":"Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates","volume":"251","author":"Hevey","year":"1998","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2006.06.004_bib29","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1086\/339677","article-title":"Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon","volume":"185","author":"Lee","year":"2002","journal-title":"J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2006.06.004_bib30","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.1128\/IAI.69.9.5709-5715.2001","article-title":"Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system","volume":"69","author":"Lee","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2006.06.004_bib31","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/viro.1997.8883","article-title":"Antigenicity and vaccine potectial of Marburg virus glycoprotein expressed by baculovirus recombinants","volume":"239","author":"Hevey","year":"1997","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.vaccine.2006.06.004_bib32","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/IAI.59.6.1961-1965.1991","article-title":"Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals","volume":"59","author":"Iacono-Connors","year":"1991","journal-title":"Infect Immun"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06007080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X06007080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T18:12:08Z","timestamp":1586974328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X06007080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":32,"journal-issue":{"issue":"47-48","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S0264410X06007080"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2006.06.004","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2006,11]]}}}